Dr. Reddy's Laboratories

NSE: DRREDDY · Pharma

₹1,276.25

▲ +2.10%

SELL

Illustrative research · not investment advice Demo price · quote unavailable · Fundamentals and research: sample dataset (30 Oct 2026)

Price chart

Illustrative price history · not actual market candles

A. Company overview

Global generics and APIs pharma company.

Market cap

₹2,21,32,072 Cr

Industry / Sector

Pharma

Segments

Website

Visit ↗

Global GenericsPSAIBiosimilars

B. Fundamental analysis (illustrative)

Revenue growth

+14.15%

Net profit growth

+7.97%

Operating margin

24.15%

EBITDA margin

29.73%

ROE

18.22%

ROCE

20.94%

Debt / Equity

1.24

EPS

₹23.53

Operating cash flow

₹30,600 Cr

Working capital

₹9,871 Cr

5-year revenue & profit (₹ Cr)

C. Financial statements (illustrative)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Revenue	77,237	85,055	96,099	1,07,459	1,23,393
EBITDA	22,055	22,942	28,044	30,346	36,683
Net profit	13,784	14,339	17,527	18,966	22,927
EPS (₹)	16.47	18.35	20.24	22.12	24

D. Valuation analysis

P/E

54.23

P/B

4.39

EV/EBITDA

30.75

Price/Sales

4.35

EPS

₹23.53

Dividend yield

1.59%

Peer comparison — Pharma

Company	CMP	P/E	P/B	ROE	D/E
Dr. Reddy's Laboratories	1,276.25	54.23	4.39	18.22%	1.24
Sun Pharmaceutical	1,781.5	55.43	3.1	22.33%	0.13
Cipla	1,489.5	36.69	3.85	10.69%	1.42
Divi's Laboratories	6,383.65	23.57	3.34	29.57%	0.89

E. Technical analysis

RSI (14)

61.3

MACD

8.59

Support

₹1,212.44

Resistance

₹1,352.83

Volume

71,38,682

Illustrative technical charts · not actual market history

Candlestick (last 50 sessions)

Price with 50-DMA & 200-DMA, volume

Fibonacci retracement levels

23.6% · ₹1293.78

38.2% · ₹1273.22

50.0% · ₹1256.60

61.8% · ₹1239.98

F. Shareholding pattern

Promoter9.31%

FII32.02%

DII26.07%

of which Mutual Funds10.58%

Public32.6%

G. SWOT analysis

Strengths

Established position in Pharma
ROE of 18.22% in demo data

Weaknesses

Elevated leverage
Cyclical exposure

Opportunities

Domestic demand growth
Expansion in Global Generics

Threats

Regulatory changes
Competitive intensity

Illustrative template points for demonstration.

H. Research conclusion

Financial strength

Moderate leverage to monitor

Business quality

High capital efficiency

Valuation

Premium valuation

Growth

Sales growth of 14.15%

Risk assessment

High risk

Overall

Illustrative SELL opinion · target ₹1,124.75 · stop loss ₹1,180.03

I. Corporate actions

Dividend history (₹/share)

Year	Dividend
FY22	16.23
FY23	17.45
FY24	18.67
FY25	19.88
FY26	21.1

Bonus, splits & announcements

Bonus history: none in demo dataset
Stock split history: none in demo dataset
Board meeting for quarterly results — demo announcement